Imaging software developer Median Technologies said that its iBiopsy platform has shown promising results in measuring antitumor immune response, potentially helping to identify patients who are responding to treatment.
In a retrospective study involving 44 patients with primary liver cancer, Median found that the CD8 signature of the deep learning-based iBiopsy platform was a better predictor -- with an area under the curve (AUC) of 0.93 -- of the tumor microenvironment than traditional radiomics methods, which only yielded an AUC of 0.67. What's more, the iBiopsy CD8 signature was also shown to be predictive of patient prognosis, according to the firm.
Median noted that the study findings now need to be confirmed in larger, independent cohorts.
